Objective: Current epidemiologic knowledge about bipolar disorder (BD) in Canada is inadequate. To date, only 3 prevalence studies have been conducted: only 1 was based on a national sample, and none distinguished between BD I and II. The objective of this study was to estimate the prevalence of BD I and II in Canada in 2012.
Abbreviations

Clinical Implications
• The prevalence of CIDI-assessed BD in Canada resembles that of other countries.
• The frequency of lithium use was low relative to the apparent prevalence of BD I and II.
• Major deficits remain in the understanding of BD epidemiology in Canada.
Limitations
• The estimated prevalence of BD I and II may have been underestimated owing to recall bias, as suggested by declining age-specific prevalence.
• The limited overlap between CIDI-defined diagnoses, self-reported diagnoses, and lithium use raises concern about the validity of the CIDI module for BD. P revalence estimates serve as a foundation for planning population health interventions, monitoring health system progress, and setting research priorities. To date, only 3 general population studies of BD prevalence have been conducted in Canada, and only 1 of these used a nationally representative sample. Two community-based studies, conducted in Edmonton 1 and Ontario, 2 obtained prevalence estimates for a manic episode of 0.4% (lifetime) and 0.4% to 0.6% (6 to 12 month), respectively. More recently, a study using data from the 2002 CCHS-Mental Health and Well-being 3 estimated a lifetime prevalence of mania at 2.2%. 4 However, it has since been suspected that the diagnostic tool used to diagnose BD I in the latter study may have overestimated the prevalence. 5 Also, a substantial limitation of the previous studies is their inability to distinguish between BD I and BD II-no available Canadian estimates have made this distinction. The goal of our study was to employ newly calibrated algorithms to produce national estimates of BD I and BD II prevalence.
Method
Data Source
The 2012 CCHS was a cross-sectional survey conducted by Statistics Canada. Detailed information about the survey is available from Statistics Canada. 6 Information was collected from a nationally representative sample of household residents aged 15 years and older living in the 10 provinces (this target population covers about 97% of the Canadian general population). People excluded from the survey were living on reserve settlements, institutionalized, and full-time members of the Canadian Armed Forces. The survey employed a multi-stage probability-sampling technique. One person aged 15 years or older per sampled household was randomly selected to participate. Interviews were conducted by trained lay interviewers. The majority of interviews (87%) were conducted in person.
CIDI Classification
Interviews were based on the World Mental Health CIDI, 7 a fully structured interview intended to derive diagnoses of numerous mental disorders. Respondents answered a series of questions about possible symptoms of mania, hypomania, and MDE. Algorithms determined the presence or absence of BD I and BD II based on the answers received. The algorithms were updated since the 2002 CCHS through calibration adjustments based on clinical reappraisal studies intended to increase the accuracy of estimation. 7 These recalibrated algorithms were used to derive a diagnosis according to operationalizations of DSM-IV 8 definitions and criteria. Respondents were classified as having BD I if they had ever experienced 1) at least 6 symptoms of mania; and 2) at least 2 super-symptoms (becoming overly friendly, behaving inappropriately, getting involved in foolish schemes, getting into financial trouble, and believing that they were someone else or connected to a famous person).
Respondents were classified as having BD II if they ever experienced 1) distinctly elevated mood lasting 7 days or longer, at least 3 symptoms of mania, euphoria, or racing thoughts, and marked impairment in social or occupational functioning (or symptoms causing less severe impairment, but lasting at least 14 days);
2) at least 1 lifetime MDE; and
3) did not meet the criteria for lifetime manic epdisode. 5 Notably, the recalibrations do not completely align at the level of face validity with the DSM-IV diagnostic criteria. For example, the concept of super-symptoms and a 14-day duration are not present in DSM-IV (nor are they present in peu de personnes qui prenaient du lithium étaient positives à la CIDI, ce qui soulève des préoccupations sur la validité de l'évaluation du TB par la CIDI.
Conclusions : Ces estimations de la prévalence sont conformes à celles de la littérature antérieure. Cependant, la prudence est de mise lorsqu'on interprète des études dans la population générale qui utilisent le TB défini par la CIDI, étant donné la possibilité d'une classification erronée.
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Prevalence of Bipolar I and II Disorder in Canada DSM-5 9 ). They represent adjustments intended to improve accuracy of prevalence estimation based on clinical calibration work. The interview used in the 2012 CCHS is the same version as the one used in the clinical calibration study and was not modified by Statistics Canada.
Self-Reported Bipolar Disorder
Respondents were asked about a list of conditions diagnosed by a health professional that had lasted or were expected to last more than 6 months. For self-reported BD, respondents were asked, "Do you have a mood disorder such as depression, bipolar disorder, mania or dysthymia?" People who answered yes were then asked what disorder they were diagnosed with (more than one response was permitted).
Lithium Use
Medication use in the sample was collected as drug identification numbers for all medications taken within the 2 days preceding the interview. Lithium was of particular interest in this study because lithium is a first-line treatment for prophylaxis of BD, as recommended by current Canadian guidelines, 10 and is likely to be used more exclusively to treat BD than other mood stabilizers.
Statistical Analysis
Data analysis was carried out at the Prairie Regional Data Centre at the University of Calgary using the statistical software, Stata, version 13.0. 11 Crude and sex-specific prevalence were estimated as frequencies with associated 95% confidence intervals. The age-specific pattern was examined using generalized linear models of the binomial family with the log link function. The age-squared term was included in the model owing to a better fit, based on comparing Akaike Information Criterion and Bayesian Information Criterion 11 between models, with and without the quadratic age term. Models were also assessed for an age-sex interaction using likelihood ratio tests and Wald tests. Analyses were carried out separately for CIDI classified BD I and BD II, self-reported BD, and lithium use. All analyses were weighted using the recommended procedures and replicate bootstrap weights provided by Statistics Canada to produce valid confidence intervals and results representative of the target population. For the remainder of the study, prevalence estimates for BD (CIDIclassified and self-reported) refer to lifetime prevalence. In this case, lifetime prevalence is the most appropriate measurement choice because diagnostic criteria for BD relies on major mood episodes experienced at any time during the life course. In addition, the dynamic nature of the illness (people may experience any of manic, hypomanic, mixed and [or] depressive episodes in a given year) makes it difficult to define past-year or point prevalence in such a way that effectively captures all people with BD.
Results
The national response rate for the survey was 68.9% (n = 25 113). Incomplete data prevented classification of some people into 1 or more subgroups of interest, the proportions of missing data were as follows: CIDI BD I (0.39%), CIDI BD II (0.25%), self-reported BD (0.06%), and lithium use (0.82%).
The estimated prevalence of CIDI-classified BD I and BD II in Canada in 2012 was 0.87% (95% CI 0.67% to 1.07%) and 0.57% (95% CI 0.44% to 0.71%), respectively. The estimated prevalence of self-reported BD was 0.87% (95% CI 0.65% to 1.07%), and the prevalence of lithium use in the sample was 0.14% (95% CI 0.08% to 0.20%).
Sex-specific prevalence estimates were similar within each subgroup.
Generalized linear models, including age as a quadratic term, provided a better fit than those that assumed a linear association between age and log prevalence; therefore, analyses included the quadratic age function. Likelihood ratio and Wald tests showed no evidence of interactions between sex and age or sex and age-squared for any of the CIDI-classified BD I or BD II, self-reported BD, or lithium models. Sex did not appear to modify or confound the association between age and prevalence, and, therefore, was not included in the final model. Age-specific prevalence for CIDI-classified BD I and BD II and self-reported BD appear to increase with age until mid-30s, then subsequently decline. The prevalence of lithium use appears to increase steadily with age, then plateau at about 55 years of age. Figure 1 shows a plot of the fitted values with age for the generalized linear models estimating prevalence of each of CIDI-classified BD I and BD II, self-reported BD, and lithium use. Table 1 shows cross-tabulations of the CIDI-defined BD I and BD II, self-reported BD, and lithium use subgroups. Among people using lithium, most (74%) reported that they had been diagnosed with BD, consistent with expectation. However, the overlap of the other categories was low. For example, only 19% of people with CIDI-defined BD I reported a diagnosis of BD, and of those who self-reported a BD diagnosis, only 19% were positive for BD I on the CIDI.
Discussion
The estimated prevalence of CIDI-classified BD I and BD II in Canada in 2012 was 0.87% and 0.57%, respectively. The estimated prevalence of self-reported BD was 0.87%.
Our study provides the first prevalence estimates for BD I and BD II, separately, in a nationally representative sample in Canada.
Although CIDI-classified and self-reported BD appear to provide prevalence estimates that align with that in the literature, 12 the 2 measurement methods do not appear to capture the same group of people. Among those who selfreported BD, very few met the CIDI criteria for BD I (19%) or BD II (8%). This suggests that misclassification of people may have occurred.
Lithium was used in our study as an additional referent for BD classifications. Lithium is likely to be prescribed primarily for treatment of recurrent mood disorders, particularly BD. The proportion of lithium users that selfreported BD (74%) is consistent with this expectation, but this frequency was considerably higher than the proportion of lithium users that met the CIDI criteria for either BD I (20%) or BD II (11%). Of course, the lack of agreement between these different measures may also be due to poor recognition and undertreatment of BD. In the absence of a gold standard, it is unclear to what extent misclassification occurred in each subgroup.
An additional indication that misclassification has occurred arises from the observation that both CIDI-defined subgroups showed a parabolic pattern of change in prevalence with age, with a distinct decline in prevalence from mid-to late-adulthood. This is not concordant with the trend that would be expected for a lifelong, recurrent condition in the absence of an extremely strong effect of BD on mortality. This is also in contrast to results of a systematic review that found age-specific lifetime prevalence remained relatively steady across ages 18 to 64 years. 13 The age-specific trends observed in our study may be occurring for numerous reasons. Theoretically, it could be explained, to some extent, by a reduced life expectancy among people with BD, 14 but it is unlikely that early mortality could fully explain the marked decline. Another potential explanation could be a cohort effect, with diagnoses made more frequently in more recent birth cohorts, 15 but this explanation is also unlikely because prevalence was not unexpectedly high, even in younger ages. Finally, the trend may be explained by recall bias. Studies of other mood disorders, such as depression, have observed similar declines with age when using lifetime prevalence, 16 which has led to a greater emphasis on 12-month prevalence in the more recent literature. Unfortunately, types of prevalence other than lifetime to study BD may be unsuitable because definitions of BD depend on major mood episodes that occur during the life course. Specifically, the lifetime occurrence of a manic (or hypomanic) episode determines the definitive diagnosis of BD. However, in any given year, there may only be episodes of manic and (or) hypomanic or depressive polarity. For example, people may only have an MDE during the past year, and yet have a BD I diagnosis owing to a previous manic episode. The apparent flaws of lifetime prevalence, and its vulnerability to recall bias, coupled with the need to focus on lifetime prevalence may contribute to the discrepancy in CIDI classifications. These findings appear to contrast with a study of validity of the CIDI in relation to standardized clinical assessments in the World Health Organization World Mental Health Survey Initiative. The study showed good concordance between the CIDI and Structured Clinical Interview for DSM-IV diagnoses of BD I and BD II in clinical reappraisal sample, with sensitivity and specificity of about 87% an 97%, respectively. 17 However, a specificity of 97% implies a false-positive rate of 3%, and this is not consistent with the observed prevalence of less than 1%, even if the sensitivity is zero. Even much higher specificity would result in a high proportion of CIDI-positive subjects being false positive, which, combined with suboptimal sensitivity could explain these results.
It is possible that fully structured interviews are inadequate for accurate diagnosis of BD in the general population.
Notably, earlier versions of the CIDI included diagnostic modules for psychotic disorders, 18 but the modules were excluded from later versions of the instrument because their outputs were invalid. For example, false-positive rates for psychotic symptoms, such as delusions and hallucinations, were found to be quite high, possibly owing to misunderstanding of the interview questions, lack of insight, drug-induced states, or religious beliefs,. 19, 20 Crossvalidation studies repeatedly showed poor agreement with clinical diagnoses within the National Comorbidity Survey and Epidemiologic Catchment Area studies. 21 This may be due to the inability of a rigid, fully structured interview to assess such subtle disturbances and to collect the extensive contextual information required for accurate diagnosis. 22 Similar problems may apply to the measurement of BD I and BD II in the general population using fully structured interviews. For example, it may be difficult for a fully structured diagnostic interview to distinguish a normative adolescent experience from hypomanic symptoms. 23 In Canada, mental health policy and planning still relies heavily on information collected from population surveys. If the measurement tools used in these surveys are not valid information sources, then more resources must be allocated to developing infrastructure for surveillance through administrative data. In 2010, the Public Health Agency of Canada expanded the Canadian Chronic Disease surveillance system to monitor mental illnesses, including BD. As this is a relatively new initiative, the quality of information collected is yet to be determined. However, additional surveillance using health administration data does not solve all problems, as BD is believed to be an undertreated condition and physician billing and hospital discharge data reflect only the treated prevalence.
Conclusion
Prevalence research lays the framework for understanding burden of disease in the population. Many countries still rely heavily on population surveys for collecting public health information and surveillance. The CIDI is one of the most widely used instruments internationally. Findings in the current study raise questions about the validity of the CIDI for measurement of BD I and BD II, and, by extension, our understanding of the epidemiology of BD to date. In light of the results of our study, it is recommended that future and past studies that use the CIDI be interpreted with caution.
